Sara Nik
Stock Analyst at H.C. Wainwright
(0.08)
# 4,627
Out of 4,662 analysts
51
Total ratings
12.5%
Success rate
-22.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRIS Curis | Reiterated: Buy | $43 | $1.72 | +2,400.00% | 10 | Aug 17, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.49 | +512.24% | 10 | Aug 17, 2026 | |
| TVRD Tvardi Therapeutics | Maintained: Buy | $9 | $1.88 | +378.72% | 4 | Aug 14, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $22 | $0.572 | +3,746.15% | 17 | Jul 31, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 14.00 | kr 1.78 | +687.84% | 9 | Jul 2, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.3096 | n/a | 1 | Aug 13, 2025 |
Curis
Aug 17, 2026
Reiterated: Buy
Price Target: $43
Current: $1.72
Upside: +2,400.00%
Pasithea Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $3
Current: $0.49
Upside: +512.24%
Tvardi Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $9
Current: $1.88
Upside: +378.72%
Moleculin Biotech
Jul 31, 2026
Reiterated: Buy
Price Target: $22
Current: $0.572
Upside: +3,746.15%
Cantargia AB (publ)
Jul 2, 2026
Reiterated: Buy
Price Target: kr 14.00
Current: kr 1.78
Upside: +687.84%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.3096
Upside: n/a